Kelley CF, Acevedo-Qui?ones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, S?nchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O, PURPOSE 2 Study Team
Anti-HIV Agents; HIV Infections; Pre-Exposure Prophylaxis
Acetamides; Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Humans; Incidence; Indazoles; Injection Site Reaction; Injections, Subcutaneous; Intention to Treat Analysis; Male; Middle Aged; Tenofovir; Transgender Persons; Treatment Outcome; Young Adult
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 03; 392(13):1261-1276.
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
How Women Can Empower Themselves Against HIV
Charles R. Drew University of Medicine and Science